Antispasmodic effects of eugenol on rat airway smooth muscle

Felipe Crescêncio Lima, Dieniffer Peixoto-Neves, Maria Diana Moreira Gomes, Andrelina Noronha Coelho-de-Souza, Crystianne Calado Lima, Walter Araújo Zin, Pedro Jorge Caldas Magalhães, Lahlou Saad, José Henrique Leal-Cardoso

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This study was undertaken to assess the effects of eugenol (EUG) on tracheal muscle (TM) and the putative mechanisms underlying these effects. Cumulatively increasing concentrations (1-1000μm) of EUG did not affect the resting tonus of TM. However, EUG (1-2000μm) reduced the contractions induced by electrical field stimulation (IC 50=842.3±52.7μm), an effect that was unaltered by either 10μm montelukast (IC 50=816.1±70.1μm) or 2μm indomethacin (IC 50=693.1±170.8μm). EUG also completely relaxed the sustained contractile responses to 80mM K + (IC 50=597.3±60.6μm) and 1μm carbamoylcholine (IC 50=571.3±148.8μm), an effect that was unaltered by indomethacin (2μm). Under Ca 2+-free conditions, EUG reduced the ACh-induced contractions (IC 50=703.4±256.1μm), the CaCl 2-induced contractions in preparations pretreated with 60μm ACh in the presence of nifedipine, and the Ba 2+-induced contractions in preparations depolarized with K +. In tracheal preparations maintained in Ca 2+-containing solution, EUG (300-2000μm) relaxed the contractile response to phorbol dibutyrate (1μm), an activator of protein kinase C. It is concluded that in TM, EUG induces a myogenic antispasmodic effect (not modulated by arachidonic acid derivatives) either through various mechanisms almost with the same pharmacological potency or via an action on a step common to all of them. These mechanisms seem to include blockade of voltage- and receptor-operated Ca 2+ channels, IP 3-induced Ca 2+ release from sarcoplasmic reticulum and reduction of the sensitivity of contractile proteins to Ca 2+.

Original languageEnglish (US)
Pages (from-to)690-699
Number of pages10
JournalFundamental and Clinical Pharmacology
Volume25
Issue number6
DOIs
StatePublished - Dec 1 2011

Fingerprint

Eugenol
Parasympatholytics
Smooth Muscle
montelukast
Indomethacin
Contractile Proteins
Muscles
Muscle Tonus
Sarcoplasmic Reticulum
Carbachol
Nifedipine
Arachidonic Acid
Protein Kinase C
Electric Stimulation
Pharmacology

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Lima, F. C., Peixoto-Neves, D., Gomes, M. D. M., Coelho-de-Souza, A. N., Lima, C. C., Araújo Zin, W., ... Leal-Cardoso, J. H. (2011). Antispasmodic effects of eugenol on rat airway smooth muscle. Fundamental and Clinical Pharmacology, 25(6), 690-699. https://doi.org/10.1111/j.1472-8206.2010.00892.x

Antispasmodic effects of eugenol on rat airway smooth muscle. / Lima, Felipe Crescêncio; Peixoto-Neves, Dieniffer; Gomes, Maria Diana Moreira; Coelho-de-Souza, Andrelina Noronha; Lima, Crystianne Calado; Araújo Zin, Walter; Magalhães, Pedro Jorge Caldas; Saad, Lahlou; Leal-Cardoso, José Henrique.

In: Fundamental and Clinical Pharmacology, Vol. 25, No. 6, 01.12.2011, p. 690-699.

Research output: Contribution to journalArticle

Lima, FC, Peixoto-Neves, D, Gomes, MDM, Coelho-de-Souza, AN, Lima, CC, Araújo Zin, W, Magalhães, PJC, Saad, L & Leal-Cardoso, JH 2011, 'Antispasmodic effects of eugenol on rat airway smooth muscle', Fundamental and Clinical Pharmacology, vol. 25, no. 6, pp. 690-699. https://doi.org/10.1111/j.1472-8206.2010.00892.x
Lima, Felipe Crescêncio ; Peixoto-Neves, Dieniffer ; Gomes, Maria Diana Moreira ; Coelho-de-Souza, Andrelina Noronha ; Lima, Crystianne Calado ; Araújo Zin, Walter ; Magalhães, Pedro Jorge Caldas ; Saad, Lahlou ; Leal-Cardoso, José Henrique. / Antispasmodic effects of eugenol on rat airway smooth muscle. In: Fundamental and Clinical Pharmacology. 2011 ; Vol. 25, No. 6. pp. 690-699.
@article{6520270545d14b3b98a8e82472d6908a,
title = "Antispasmodic effects of eugenol on rat airway smooth muscle",
abstract = "This study was undertaken to assess the effects of eugenol (EUG) on tracheal muscle (TM) and the putative mechanisms underlying these effects. Cumulatively increasing concentrations (1-1000μm) of EUG did not affect the resting tonus of TM. However, EUG (1-2000μm) reduced the contractions induced by electrical field stimulation (IC 50=842.3±52.7μm), an effect that was unaltered by either 10μm montelukast (IC 50=816.1±70.1μm) or 2μm indomethacin (IC 50=693.1±170.8μm). EUG also completely relaxed the sustained contractile responses to 80mM K + (IC 50=597.3±60.6μm) and 1μm carbamoylcholine (IC 50=571.3±148.8μm), an effect that was unaltered by indomethacin (2μm). Under Ca 2+-free conditions, EUG reduced the ACh-induced contractions (IC 50=703.4±256.1μm), the CaCl 2-induced contractions in preparations pretreated with 60μm ACh in the presence of nifedipine, and the Ba 2+-induced contractions in preparations depolarized with K +. In tracheal preparations maintained in Ca 2+-containing solution, EUG (300-2000μm) relaxed the contractile response to phorbol dibutyrate (1μm), an activator of protein kinase C. It is concluded that in TM, EUG induces a myogenic antispasmodic effect (not modulated by arachidonic acid derivatives) either through various mechanisms almost with the same pharmacological potency or via an action on a step common to all of them. These mechanisms seem to include blockade of voltage- and receptor-operated Ca 2+ channels, IP 3-induced Ca 2+ release from sarcoplasmic reticulum and reduction of the sensitivity of contractile proteins to Ca 2+.",
author = "Lima, {Felipe Cresc{\^e}ncio} and Dieniffer Peixoto-Neves and Gomes, {Maria Diana Moreira} and Coelho-de-Souza, {Andrelina Noronha} and Lima, {Crystianne Calado} and {Ara{\'u}jo Zin}, Walter and Magalh{\~a}es, {Pedro Jorge Caldas} and Lahlou Saad and Leal-Cardoso, {Jos{\'e} Henrique}",
year = "2011",
month = "12",
day = "1",
doi = "10.1111/j.1472-8206.2010.00892.x",
language = "English (US)",
volume = "25",
pages = "690--699",
journal = "Fundamental and Clinical Pharmacology",
issn = "0767-3981",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Antispasmodic effects of eugenol on rat airway smooth muscle

AU - Lima, Felipe Crescêncio

AU - Peixoto-Neves, Dieniffer

AU - Gomes, Maria Diana Moreira

AU - Coelho-de-Souza, Andrelina Noronha

AU - Lima, Crystianne Calado

AU - Araújo Zin, Walter

AU - Magalhães, Pedro Jorge Caldas

AU - Saad, Lahlou

AU - Leal-Cardoso, José Henrique

PY - 2011/12/1

Y1 - 2011/12/1

N2 - This study was undertaken to assess the effects of eugenol (EUG) on tracheal muscle (TM) and the putative mechanisms underlying these effects. Cumulatively increasing concentrations (1-1000μm) of EUG did not affect the resting tonus of TM. However, EUG (1-2000μm) reduced the contractions induced by electrical field stimulation (IC 50=842.3±52.7μm), an effect that was unaltered by either 10μm montelukast (IC 50=816.1±70.1μm) or 2μm indomethacin (IC 50=693.1±170.8μm). EUG also completely relaxed the sustained contractile responses to 80mM K + (IC 50=597.3±60.6μm) and 1μm carbamoylcholine (IC 50=571.3±148.8μm), an effect that was unaltered by indomethacin (2μm). Under Ca 2+-free conditions, EUG reduced the ACh-induced contractions (IC 50=703.4±256.1μm), the CaCl 2-induced contractions in preparations pretreated with 60μm ACh in the presence of nifedipine, and the Ba 2+-induced contractions in preparations depolarized with K +. In tracheal preparations maintained in Ca 2+-containing solution, EUG (300-2000μm) relaxed the contractile response to phorbol dibutyrate (1μm), an activator of protein kinase C. It is concluded that in TM, EUG induces a myogenic antispasmodic effect (not modulated by arachidonic acid derivatives) either through various mechanisms almost with the same pharmacological potency or via an action on a step common to all of them. These mechanisms seem to include blockade of voltage- and receptor-operated Ca 2+ channels, IP 3-induced Ca 2+ release from sarcoplasmic reticulum and reduction of the sensitivity of contractile proteins to Ca 2+.

AB - This study was undertaken to assess the effects of eugenol (EUG) on tracheal muscle (TM) and the putative mechanisms underlying these effects. Cumulatively increasing concentrations (1-1000μm) of EUG did not affect the resting tonus of TM. However, EUG (1-2000μm) reduced the contractions induced by electrical field stimulation (IC 50=842.3±52.7μm), an effect that was unaltered by either 10μm montelukast (IC 50=816.1±70.1μm) or 2μm indomethacin (IC 50=693.1±170.8μm). EUG also completely relaxed the sustained contractile responses to 80mM K + (IC 50=597.3±60.6μm) and 1μm carbamoylcholine (IC 50=571.3±148.8μm), an effect that was unaltered by indomethacin (2μm). Under Ca 2+-free conditions, EUG reduced the ACh-induced contractions (IC 50=703.4±256.1μm), the CaCl 2-induced contractions in preparations pretreated with 60μm ACh in the presence of nifedipine, and the Ba 2+-induced contractions in preparations depolarized with K +. In tracheal preparations maintained in Ca 2+-containing solution, EUG (300-2000μm) relaxed the contractile response to phorbol dibutyrate (1μm), an activator of protein kinase C. It is concluded that in TM, EUG induces a myogenic antispasmodic effect (not modulated by arachidonic acid derivatives) either through various mechanisms almost with the same pharmacological potency or via an action on a step common to all of them. These mechanisms seem to include blockade of voltage- and receptor-operated Ca 2+ channels, IP 3-induced Ca 2+ release from sarcoplasmic reticulum and reduction of the sensitivity of contractile proteins to Ca 2+.

UR - http://www.scopus.com/inward/record.url?scp=80054935225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054935225&partnerID=8YFLogxK

U2 - 10.1111/j.1472-8206.2010.00892.x

DO - 10.1111/j.1472-8206.2010.00892.x

M3 - Article

VL - 25

SP - 690

EP - 699

JO - Fundamental and Clinical Pharmacology

JF - Fundamental and Clinical Pharmacology

SN - 0767-3981

IS - 6

ER -